Programmed cell death receptor ligand 1 modulates the regulatory t cells' capacity to repress shock/sepsisyinduced indirect acute lung injury by recruiting phosphatase src homology region 2 domain-containing phosphatase 1

Shock

Volumn 43, Issue 1, 2015, Pages 47-54

  Tang, Lunxian ^a   Bai, Jianwen ^a   Chung, Chun Shiang ^b   Lomas Neira, Joanne ^b   Chen, Yaping ^b   Huang, Xin ^b   Ayala, Alfred ^b  

^a TONGJI UNIVERSITY   (China)

^b BROWN UNIVERSITY   (United States)

Author keywords

Apoptosis; CTLA 4; Neutrophil influx; Programmed death receptor 1; SHP 2

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; KERATINOCYTE DERIVED CHEMOKINE; PHOSPHATASE; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN TYROSINE PHOSPHATASE; CASP3 PROTEIN, MOUSE; CASPASE 3; CD274 PROTEIN, MOUSE; CYTOKINE; PROTEIN TYROSINE PHOSPHATASE SHP 1; PTPN6 PROTEIN, MOUSE;

ACUTE LUNG INJURY; ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; HEMORRHAGIC SHOCK; INNATE IMMUNITY; LUNG PARENCHYMA; NONHUMAN; PROTEIN DOMAIN; REGULATORY T LYMPHOCYTE; WESTERN BLOTTING; ANIMAL; COMPLICATION; ENZYME ACTIVATION; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LUNG; MALE; MOUSE; PATHOLOGY; SEPSIS;

ACUTE LUNG INJURY; ANIMALS; ANTIGENS, CD274; APOPTOSIS; CASPASE 3; CYTOKINES; ENZYME ACTIVATION; LUNG; MALE; MICE; MICE, KNOCKOUT; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; SEPSIS; SHOCK, HEMORRHAGIC; T-LYMPHOCYTES, REGULATORY;

EID: 84925874107     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000000247     Document Type: Conference Paper

References (36)

1. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS: Acute respiratory distress syndrome: the Berlin definition. JAMA 307(23):2526-2533, 2012.
2. Ferguson ND, Fan E, Camporota L, Antonelli M, Anzueto A, Beale R, Brochard L, Brower R, Esteban A, Gattinoni L, et al.: The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med 38(10):1573-1582, 2012.
3. Serhan CN, Savill J: Resolution of inflammation: the beginning programs the end. Nat Immunol 6(12):1191-1197, 2005.
4. + Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury. J Clin Invest 119(10):2898-2913, 2009.
5. Aggarwal NR, D'Alessio FR, Tsushima K, Sidhaye VK, Cheadle C, Grigoryev DN, Barnes KC, King LS: Regulatory T cellYmediated resolution of lung injury: identification of potential target genes via expression profiling. Physiol Genomics 41(2):109-119, 2010.
6. + regulatory T cells and balancing anti-and pro-inflammatory factors. Cell Physiol Biochem 27(5):587-596, 2011.
7. + regulatory T cells (Tregs) and PD-1-s immunomodulatory effects. J Leukoc Biol 96(5):809-820, 2014.
8. Yang XO, Nurieva R, Martinez GJ, Kang HS, Chung Y, Pappu BP, Shah B, Chang SH, Schluns KS, Watowich SS, et al.: Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 29(1): 44-56, 2008.
9. Francisco LM, Sage PT, Sharpe AH: The PD-1 pathway in tolerance and au-toimmunity. Immunol Rev 236:219-242, 2010.
10. Gianchecchi E, Delfino DV, Fierabracci A: Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun Rev 12(11):1091-1100, 2013.
11. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL: SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 173(2):945-954, 2004.
12. Kaufmann DE, Walker BD: PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J Immunol 182(10):5891-5897, 2009.
13. Jin Y, Chauhan SK, El Annan J, Sage PT, Sharpe AH, Dana R: A novel function for programmed death ligand-1 regulation of angiogenesis. Am J Pathol 178(4):1922-1929, 2011.
14. Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L: B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111(7):3635-3643, 2008.
15. + T cells in indirect pulmonary lung injury. J Immunol 183(5):3472-3480, 2009.
16. Monaghan SF, Thakkar RK, Heffernan DS, Huang X, Chung CS, Lomas JL, Cioffi WG, Ayala A: Mechanisms of indirect acute lung injury: a novel role for the coinhibitory receptor, programmed death-1. Ann Surg 255(1): 158-164, 2012.
17. Ayala A, Chung CS, Lomas JL, Song GY, Doughty LA, Gregory SH, Cioffi WG, LeBlanc BW, Reichner J, Simms HH, et al.: Shock induced neutrophil mediated priming for acute lung injury in mice: divergent effects of TLR-4 and TLR-4/FasL deficiency. Am J Pathol 161(6):2283-2294, 2002.
18. Bai J, Tang L, Lomas JL, Chen Y, McLeish KR, Uriarte SM, Chung CS, Ayala A: TAT-SNAP-23 treatment inhibits the priming of neutrophil functions contributing to shock and/or sepsis-induced extra-pulmonary acute lung injury [published online ahead of print]. Innate Immun 2014. Jan 3 [Epub ahead of print].
19. Lomas JL, Chung CS, Grutkoski PS, LeBlanc BW, Lavigne L, Reichner J, Gregory SH, Doughty LA, Cioffi WG, Ayala A: Differential effects of MIP-2 and KC on hemorrhage induced neutrophil priming for lung inflammation: assessment by adoptive cell transfer in mice. Shock 19:358-365, 2003.
20. + T-regulatory-cells to immune suppression in sepsis. Shock 27(3): 251-257, 2007.
21. Hutchins NA, Wang F, Wang Y, Chung CS, Ayala A: Kupffer cells potentiate liver sinusoidal endothelial cell injury in sepsis by ligating programmed cell death ligand-1. J Leukoc Biol 94(5):963-970, 2013.
22. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ: The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 8(3):239-245, 2007.
23. Huang X, Chen Y, Chung CS, Yuan Z, Monaghan SF, Wang F, Ayala A: Identification of B7-H1 as a novel mediator of the innate immune/proinflammatory response as well as a possible myeloid cell prognostic bio-marker in sepsis. J Immunol 192(3):1091-1099, 2014.
24. Amarnath S, Mangus CW, Wang JC, Wei F, He A, Kapoor V, Foley JE, Massey PR, Felizardo TC, Riley JL, et al.: The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med 3(111):111-120, 2011.
25. Amarnath S, Costanzo CM, Mariotti J, Ullman JL, Telford WG, Kapoor V, Riley JL, Levine BL, June CH, Fong T, et al.: Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1. PLoS Biol 8(2):e1000302, 2010.
26. +) Treg and liver tolerance induction in mice. Transplant Proc 45(5):1853-1855, 2013.
27. Li P, Mao L, Liu X, Gan Y, Zheng J, Thomson AW, Gao Y, Chen J, Hu X: Essential role of program death 1-ligand 1 in regulatory T-cellYafforded protection against blood-brain barrier damage after stroke. Stroke 45(3): 857-864, 2014.
28. Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T: Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phos-phatase SHP2. J Exp Med 209(6):1201-1217, 2012.
29. Zhang J, Somani AK, Siminovitch KA: Roles of the SHP-1 tyrosine phospha-tase in the negative regulation of cell signalling. Semin Immunol 12(4): 361-378, 2000.
30. Pao LI, Badour K, Siminovitch KA, Neel BG: Nonreceptor protein-tyrosine phosphatases in immune cell signaling. Annu Rev Immunol 25:473-523, 2007.
31. Iype T, Sankarshanan M, Mauldin IS, Mullins DW, Lorenz U: The protein tyrosine phosphatase SHP-1 modulates the suppressive activity of regulatory T cells. J Immunol 185(10):6115-6127, 2010.
32. Kim JK, Klinger M, Benjamin J, Xiao Y, Erle DJ, Littman DR, Killeen N: Impact of the TCR signal on regulatory T cell homeostasis, function, and trafficking. PLoS One 4(8):e6580, 2009.
33. H17 cells. J Immunol 183(2):975-983, 2009.
34. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH: PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206(13):3015-3029, 2009.
35. Yi T, Elson P, Mitsuhashi M, Jacobs B, Hollovary E, Budd TG, Spiro T, Triozzi P, Borden EC: Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects. Oncotarget 2(12):1155-1164, 2011.
36. Naing A, Reuben JM, Camacho LH, Gao H, Lee BN, Cohen EN, Verschraegen C, Stephen S, Aaron J, Hong D, et al.: Phase I dose escalation study of sodium stibogluconate (SSG), a protein tyrosine phosphatase inhibitor, combined with interferon alpha for patients with solid tumors. J Cancer 2:81-89, 2011.